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Abstract: Vitamin B12 is essential for DNA synthesis and for cellular energy production. 
This review aims to outline the metabolism of vitamin B12, and to evaluate the causes and 
consequences of sub-clinical vitamin B12 deficiency. Vitamin B12 deficiency is common, 
mainly due to limited dietary intake of animal foods or malabsorption of the vitamin. 
Vegetarians are at risk of vitamin B12 deficiency as are other groups with low intakes of 
animal foods or those with restrictive dietary patterns. Malabsorption of vitamin B12 is 
most commonly seen in the elderly, secondary to gastric achlorhydria. The symptoms of 
sub-clinical deficiency are subtle and often not recognized. The long-term consequences of 
sub-clinical deficiency are not fully known but may include adverse effects on pregnancy 
outcomes, vascular, cognitive, bone and eye health. 
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Vitamin B12 deficiency was first described in 1849, and was considered to have a fatal outcome 
until 1926 when a diet of liver, high in vitamin B12, was shown to slow the disease process. Much is 
now known about the biochemistry and metabolism of vitamin B12, however, the diagnosis of its 
deficiency has become more complicated with the classification of a “sub-clinical” deficiency 
category, characterized by serum vitamin B12 concentrations that were once considered to be adequate. 
Vitamin B12 deficiency was previously thought to take many years to develop, and only in strict 
vegetarians or those with pernicious anaemia. More recent research has suggested that there are disease 
implications associated with sub-clinical B12 deficiency, which develop most commonly due to 
malabsorption or dietary inadequacy. The rates of sub-clinical deficiency of vitamin B12 are high in 
OPEN ACCESSNutrients 2010, 2                                       
 
 
300
developing countries, in the elderly, and in vegetarian populations. The long term consequences are 
not fully known but may include adverse effects on pregnancy outcomes and aspects of ageing. 
1. Vitamin B12 Function  
Vitamin B12 also known as cobalamin, comprises a number of forms including cyano-, methyl-, 
deoxyadenosyl- and hydroxy-cobalamin. The cyano form, which is used in supplements, is found in 
trace amounts in food [1]. The other forms of cobalamin can be converted to the methyl- or 5-
deoxyadenosyl forms that are required as co factors for methionine synthase and L-methyl-malonyl-
CoA mutase. 
Methionine synthase is essential for the synthesis of purines and pyrimidines. The reaction depends 
on methyl cobalamin as a co-factor and is also dependent on folate, in which the methyl group of 
methyltetrahydrofolate is transferred to homocysteine to form methionine and tetrahydrofolate. A 
deficiency of vitamin B12 and the interruption of this reaction leads to the development of 
megaloblastic anaemia. Folate deficiency independent of vitamin B12 also causes megaloblastic 
anaemia [2]. Methylmalonyl CoA mutase converts methylmalonyl CoA to succinyl CoA, with 5-deoxy 
adenosyl cobalamin required as a cofactor. It is a defect in this reaction, and the subsequent 
accumulation of methylmalonyl CoA that is thought to be responsible for the neurological effects in 
vitamin B12 deficiency [2]. 
Serum vitamin B12 is bound to proteins known as transcobalamins (TC). The majority of the 
vitamin, approximately 80%, is transported on the inactive TCI (also called haptocorrin). The active 
transport protein for vitamin B12 is transcobalamin II (TCII), which caries about 20% of the vitamin in 
the circulation [3]. Holo-transcobalamin (holo-TC) is TCII with attached cobalamin, which delivers 
vitamin B12 to cells. A low serum vitamin B12 concentration can be associated with a deficiency of 
TCI, while TCII levels and so vitamin B12 status remain adequate [4]. 
2. Biochemical Assessment of Vitamin B12 Status 
Traditionally vitamin B12 status is assessed by its concentrations in serum, however, concerns have 
been raised about the use of serum vitamin B12 measurements alone. Although low serum vitamin B12 
concentrations are a sensitive indicator of vitamin B12 deficiency and high vitamin B12 concentrations 
generally indicate sufficiency, the interpretation of the intermediate range of vitamin B12 
concentrations is unclear [4]. 
Methylmalonic acid (MMA) and homocysteine (tHcy) are recognized indicators of vitamin B12 
status. Their measurement has highlighted the existence of sub-clinical deficiency, the consequences of 
which are still being elucidated. MMA is considered to be the specific indicator of cobalamin 
metabolism, and tHcy is raised in vitamin B12 deficiency along with deficiencies of folate and vitamin 
B6. These biomarkers can be confounded by physiological or environmental conditions. Plasma tHcy 
concentrations are elevated also with renal impairment, polymorphisms in methylenetetrahydrofolate 
reductase (MTHFR), or the use of some medication. Plasma MMA concentrations are elevated also in 
renal insufficiency, common in older people [4,5].  
It has been recommended by some authors [6,7] that measuring serum vitamin B12 concentrations 
and following up low values with MMA measurements is an appropriate strategy for the assessment of Nutrients 2010, 2                                       
 
 
301
vitamin B12 status. However, the threshold of vitamin B12 at which further testing should occur is 
controversial. A study of serum vitamin B12, MMA and tHcy concentrations indicates that if a lower 
limit of normal (200 ng/L or 147 pmol/L) is used, patients with increased MMA would be missed, 
however, if higher values (500 ng/L or 370 pmol/L) are used, most patients would need follow-up 
MMA tests which may be within the normal range [8]. Carmel recommends a composite criteria based 
on serum vitamin B12 < 148 pmol/L, or 148–258 pmol/L and MMA > 0.30μmol/L, or tHcy >   
13 nmol/L (females) and >15 nmol/L (males) be used to define inadequate vitamin B12 status [9]. 
Studies that have assessed the use of holo-TC as a marker of vitamin B12 status show similarity in 
specificity and sensitivity to serum vitamin B12 concentrations. However, when used in combination 
with vitamin B12 the predictive value for determining vitamin B12 deficiency is improved [10]. 
3. Absorption 
Vitamin B12 is bound to protein in food and is available for absorption after it has been cleaved 
from protein by the hydrochloric acid produced by the gastric mucosa. The released cobalamin then 
attaches to R protein and passes into the duodenum where the R protein is removed and free cobalamin 
binds to Intrinsic Factor (IF). The IF-cobalamin complex is absorbed by the distal ileum and requires 
calcium [2]. Vitamin B12 enters the circulation about 3–4 hours later bound to TC.  
Vitamin B12 is secreted in bile and reabsorbed via the enterohepatic circulation by ileal receptors 
which require IF, thus the development of vitamin B12 deficiency is likely to be more rapid in patients 
with pernicious anaemia as IF is lacking [3]. Vitamin B12 is excreted via the faeces, which is composed 
of unabsorbed biliary vitamin B12, gastrointestinal cells and secretions, and vitamin B12 synthesised by 
bacteria in the colon. It is estimated that daily vitamin B12 losses are in proportion to body stores with 
approximately 0.1% excreted per day [11]. Excessive vitamin B12 in the circulation, e.g., such as after 
injections, usually exceeds the binding capacity of TC and is excreted in the urine [3].  
Historically, vitamin B12 absorption has been measured by a number of methods including whole 
body counting of radiolabeled vitamin B12, metabolic balance studies [1] or controlled feeding studies 
in vitamin B12-depleted individuals [12].    
It is known that the total amount of vitamin B12 that is absorbed increases with vitamin B12 intake 
but that the percentage absorption decreases with increasing doses [13]. One study using crystalline 
vitamin B12 supplements reported that 50% was retained at a 1 µg dose, 20% at a 5 µg dose and 5% at 
a 25 µg dose, suggesting saturation of the absorption mechanisms [14]. The absorption capacity is 
thought to recover to baseline levels within 4-6 hours allowing for efficient absorption of the next  
dose [11]. Approximately 1% of large doses of crystalline vitamin B12 found in some supplements 
(1,000µg), are absorbed through a mass action process, even in the absence of IF [15], indicating 
crystalline vitamin B12 in high doses and food vitamin B12 are absorbed by different mechanisms. 
The Schilling test was the classical procedure for assessing the absorption of vitamin B12 but is now 
rarely used. As there has been no replacement a number of individual tests must be used to diagnose 
the cause of vitamin B12 deficiency. Tests that diagnose atrophic gastritis, a common cause of vitamin 
B12 malabsorption, include gastroscopy or serum gastrin and pepsinogen levels. Specific tests for 
pernicious anaemia include IF antibodies and serum gastrin estimation. MMA and tHcy are better 
markers of vitamin B12 status, although they are not appropriate for testing absorption [16]. An Nutrients 2010, 2                                       
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overview of the medical management of vitamin B12 deficiency can be found in a recent article by 
Ralph Carmel [17]. 
4. Food Sources and Bioavailability of Vitamin B12 
Vitamin B12 is synthesised by certain bacteria in the gastrointestinal tract of animals and is then 
absorbed by the host animal. Vitamin B12 is concentrated in animal tissues, hence, vitamin B12 is found 
only in foods of animal origin [11]. Foods that are high in vitamin B12 (µg/100g) include: liver   
(26–58), beef and lamb (1–3), chicken (trace-1), eggs (1–2.5) and dairy foods (0.3–2.4). 
There are no naturally occurring bioactive forms of vitamin B12 from plant sources. Some plant 
foods contain added vitamin B12 and others e.g., seaweed and mushrooms contain vitamin B12 
analogues that are inactive in humans, although 2 studies suggest certain types of Japanese seaweed 
(nori) have prevented vitamin B12 deficiency in vegans [18]. Some foods that are contaminated or 
fermented by bacteria e.g., tempeh and Thai fish sauce, have been reported to contain vitamin B12 [18], 
although these may have low affinity with IF and may be poorly absorbed [19]. 
A number of methods have been used to determine the vitamin B12 content of foods. 
Microbiological assays using vitamin B12 requiring bacteria were used, however, they are no longer the 
reference method as measurement uncertainty is high. Radio isotope dilution assays with labeled 
vitamin B12 and hog IF are used [20]. Further advances are expected with the development of more 
specific monoclonal antibodies tests using specific binding proteins [21]. 
The bioavailability of vitamin B12 in humans is dependent on an individual’s gastrointestinal 
absorption capacity. As outlined previously, vitamin B12 absorption is complex and there are adverse 
changes with age. In view of the technical challenges and biological factors, there is little data on the 
bioavailability of dietary vitamin B12 in humans. It is thought that 1.5–2.0 µg of synthetic vitamin B12 
saturates the IF-cobalamin ileal receptors, but other studies have shown higher absorption rates [1,11]. 
In normal humans the absorption of vitamin B12 from foods has been shown to vary depending on the 
quantity and type of protein consumed [19]. Vitamin B12 from foods appear to have different 
absorption rates with better absorption from chicken and beef as compared to eggs. Studies assessing 
absorption of food bound vitamin B12 from whole foods are described in Table 1.  
5. Vitamin B12 Requirement 
The Recommended Dietary Intake (RDI) is set to prevent megaloblastic anaemia and maintain 
adequate serum vitamin B12 concentrations. It is assumed that 50% of dietary vitamin B12 is absorbed. 
The RDI and estimated average requirement (EAR) do not vary once adulthood is reached. However, 
the US and Australian Nutrient Reference Values suggest that older adults with atrophic gastritis may 
require higher intakes of vitamin B12-rich foods, vitamin B12 fortified foods or supplements [3,22]. The 
US Institute of Medicine has recommended that adults over 51 years consume most of their vitamin 
B12 from fortified foods or from supplements, again recognising the high rates of malabsorption due to 
gastritis that occurs with age. Vitamin B12 stores last several years and the development of deficiency 
is slow, however the combination of malabsorption and inadequate dietary intake will hasten 
deficiency [3].  Nutrients 2010, 2                                       
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Table 1. Bioavailability of vitamin B12 from whole foods. 
Food Type   Subjects 
Vitamin B12  
content 
% Absorption, 
mean (range)  
Analysis method 
Reference 
Mutton  
3 healthy young subjects  
0.9 µg in 100g 
portion 
65 (56–77)  
Radiolabelled 
vitamin B12 , 
whole body 
counting 
[11]  
2 healthy young subjects  
3.03 µg in 200g 
portion 
83  
2 healthy young subjects  
5.11 µg in 300g 
portion 
53  
Liver pate  
6 healthy subjects 
38 µg per serve 
9.1 (5.1–19.5)   Radiolabelled 
vitamin B12 , 
whole body 
counting 
[11]  
4 older subjects  4.5 (2.4–6.0)   
5 subjects with 
pernicious anaemia 
1.8 (0–3.7)   
Chicken 3  healthy  subjects 
0.4–0.6 µg in 100g 
portion 
65 (58–74) 
Radiolabelled 
vitamin B12 , 
faecal excretion 
studies 
[23] 
0.8–1.3 µg in 200g 
portion 
63 (48–76)   
1.3–1.9 µg in 300g 
portion 
61 (49–75)   
Fish 3  healthy  subjects 
2.1 µg in 50g 
portion 
42 
Radiolabelled 
vitamin B12 , 
faecal and 
urinary excretion 
studies 
[24] 
3.1 µg in 100g 
portion 
38   
9.2 µg in 200g 
portion 
42   
13.3 µg in 300g 
portion 
30   
Eggs: boiled, 
scrambled, fried 
18 healthy subjects 
0.9–1.4 µg in 100g 
portion 
3.7–9.2 
Radiolabelled 
vitamin B12 , 
faecal and 
urinary excretion 
[25] 
6. Vitamin B12 Deficiency  
Deficiency is usually caused by the malabsorption of vitamin B12 although dietary inadequacy is 
common in the elderly, vegans or ovo-lacto vegetarians with poor diets. Causes can also relate to 
inadequate IF production, atrophic gastritis, interference with the ileal uptake of vitamin B12 due to 
disease, resection or interference by bacterial overgrowth, drug-nutrient interactions as well as some 
less common genetic defects [3].  
Vegans who consume no foods of animal origin can meet their vitamin B12 requirement from 
fortified foods or supplements. Ovo-lacto vegetarians with only a small intake of dairy foods or eggs, 
may require supplemental vitamin B12. Pregnant and/or lactating women following vegetarian or vegan 
diets are at high risk of deficiency due to the increased metabolic demand for vitamin B12 and require 
adequate intake of vitamin B12-containing foods or supplements.  Nutrients 2010, 2                                       
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The elderly are at risk of undernutrition in general, predominately due to reduced intake related to 
illness but also due to physical capacity e.g., difficulties with food preparation, and psychological 
factors e.g., depression. Protein bound malabsorption is thought to be the most common cause of sub-
clinical vitamin B12 deficiency in the elderly and is commonly associated with some degree of atrophic 
gastritis. Gastritis or inflammation of the gastric mucosa increases with age and results in a reduction, 
or in some cases, complete loss of the acid required to cleave vitamin B12 from protein. Synthetic 
vitamin B12 remains available for absorption as it is not protein bound [3,22]. 
Pernicious anemia is the end stage of an auto-immune gastritis and results in the loss of synthesis of 
IF. It is this loss of IF that causes vitamin B12 deficiency and if untreated, megaloblastic anaemia and 
neurological complications develop. Pernicious anaemia is treated with vitamin B12 injections, or large 
doses of oral vitamin B12. Vitamin B12 deficiency will also develop after gastric antrum resection as 
this is the site of secretion of IF and acid [3].  
Reduced ileal uptake of vitamin B12 can be caused by competition for vitamin B12 in patients with 
bacterial overgrowth or parasitic infection. Resection or diseases of the ileum such as Crohn’s Disease 
or other chronic bowel inflammatory conditions also cause malabsorption of vitamin B12 [3]. 
The potential masking of vitamin B12 deficiency by folate fortification of the food supply has also 
raised some safety concerns. When vitamin B12 concentrations are low, high doses of folate 
(supplements or food fortification) allow DNA synthesis to continue, prevent megaloblastic anaemia 
and potentially “mask” vitamin B12 deficiency, potentially allowing homocysteine and MMA 
concentrations to rise and neurological damage to progress. Neurological damage in the absence of 
anaemia has been reported in 20-30% of cases of vitamin B12 deficiency [4]. In view of this and the 
effect of vitamin B12 deficiency on pregnancy outcomes [26,27], there is discussion of the need to 
fortify flour with vitamin B12. Vitamin B12 fortification of flour is most likely to benefit those with 
poor dietary intake of vitamin B12 and the elderly with food bound malabsorption, but would be 
inadequate for those with pernicious anaemia, which affects 2–4% of the US population depending on 
ethnicity [28]. Patients with pernicious anaemia require larger oral supplements (e.g., 500–1,000 µg/d) 
or intramuscular injections. In developing countries, fortification could potentially have a more 
significant impact as the population’s intake is often low. However, as yet there not enough 
intervention trials on the effect of different fortification levels of flour in different populations [29]. 
7. Drug-nutrient Interactions 
Some medications are thought to interfere with the absorption or metabolism of vitamin B12. These 
include proton pump inhibitor (PPI) medications, metformin, nitrous oxide anaesthesia, some epileptic 
medications and colchicine. 
PPI medications are commonly used in the elderly for the treatment of gastro-oesophageal reflux 
disease. PPI medications act by reducing the secretion of gastric acid and pepsin, theoretically leading 
to a decrease in the absorption of protein-bound vitamin B12. However, the current literature on PPI 
usage and vitamin B12 status is inconsistent [30-33]. The monitoring of vitamin B12 concentrations is 
recommended for patients undergoing prolonged PPI treatment, in recognition that the bioavailability 
of food-bound vitamin B12 may be compromised [3].  
Metformin is a biguanide used for the treatment of non-insulin dependent diabetes and some 
patients taking this medication develop megaloblastic anaemia [34,35]. This may relate to intestinal Nutrients 2010, 2                                       
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mobility changes or bacterial overgrowth competing for vitamin B12 in the gastrointestinal tract. It has 
also been shown that calcium improves the uptake of vitamin B12 in metformin users [35]. 
Nitrous oxide anesthesia inhibits methionine synthase and L-methylmalonyl–CoA mutase and 
produces deficiency symptoms despite concentrations of serum vitamin B12 in the normal range [36]. 
Antiepileptic drugs have been associated with low concentrations of vitamin B12, but this is 
controversial with some studies showing no change and others increased levels of vitamin B12 [37]. 
 
8. Vitamin B12 and Neural Tube Defects (NTD) 
 
NTD include spina bifida, anencephaly, and encephalocele. These are caused by the failure of the 
neural tube to close during gestation. The aetiology of NTD is not fully understood but risk factors 
include folate deficiency, genetic and environmental factors [26,27]. A significant reduction in NTD 
has been reported since folate fortification of the US food supply [38]. As folate has reduced but not 
eliminated rates of NTD, research is ongoing to determine further strategies to minimise risk. Low 
vitamin B12 status has been postulated as a potential risk factor for NTD [39] since vitamin B12 acts as 
a cofactor for methionine synthase in the folate cycle. When vitamin B12 supply is low, the folate 
needed for DNA synthesis remains trapped in the methylation cycle and cell replication is impaired. 
Studies assessing the impact of vitamin B12 status on NTD are shown in Table 2. The studies 
consistently report a 2-4 fold increased risk of NTD with low vitamin B12 status. The studies were 
undertaken in a range of population groups including those that are exposed to folate fortified foods, as 
well and non-fortified populations. 
Table 2. Case control and cohort studies of vitamin B12 and Neural Tube Defects. 
Design and 
reference 
 
Study Details 
 
Main Outcome 
 
Case control 
[39] 
81 NTD cases and 247 controls 
In cases only, plasma vitamin B12 and plasma folate 
affected maternal Red Cell Folate (multiple r = 0.68, p 
< 0.001). 
Case control 
[40] 
84 NTD pregnancies and 110 controls 
Women with lower vitamin B12 have increased risk of 
NTD.  
Cohort [41]  Vitamin B12 at 15 weeks' gestation  
Vitamin B12 <185 pmol/L associated with the highest 
risk of NTD. 
Case control 
[42] 
46 NTD pregnancies and 44 controls 
Lower serum vitamin B12 (p = 0.005) in cases 
compared to controls 
Case control 
[43] 
35 NTD neonates and parents vs 24 normal 
neonates. 
Low vitamin B12 in both the parents of child with NTD. 
Case control 
[44] 
89 NTD and 422 controls  Increased NTD risk with lower holo-TC. 
Case control 
1[45] 
36 NTD vs normal pregnancy. 
Low vitamin B12 associated with 2-3 x increased risk 
for NTD 
Case control 
[46] 
46 NTD and 73 control mothers 
For NTD holo-TC % (holo-TC/total TCII ) Q1vs Q4 
OR = 5.0 (95% CI:1.3, 19.3).  Nutrients 2010, 2                                       
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Table 2. Cont. 
Case control 
1[47] 
57 NTD cases and 186 controls  Q1 vs Q5 of vitamin B12 OR = 3.0 (95% CI:1.4, 6.3) 
Case control 
1[48] 
45 mothers and NTD children vs 83 controls 
Case mothers with vitamin B12 ≤ 185 pmol/L  
OR = 3.5-fold (95% CI:1.3, 8.9) for NTD risk. 
Case control 
[49] 
56 NTD babies and mothers vs 97 control 
children and mothers. 
Low vitamin B12 levels increase risk of NTD. 
Case control 
1[50] 
60 NTD cases and 94 controls  NTD for mothers for vitamin B12 levels ≤ 5
th % vs ≥95
th 
Case control 
[51] 
32 NTD pregnancies and 132 control 
pregnancies. 
MMA higher in cases vs controls. 
1Study performed in folate fortified population, NTD = Neural tube defects, OR (95%CI) = Odds Ratio and 
95% confidence interval, Q4 = 4
th quartile, Q5 = 5
th quintile, RBC = red blood cell, tHcy = total 
homocysteine concentration, holo-TC = holotranscobalamin II, total TCII = total transcobalamin II, MMA = 
methylmalonic acid 
 
9. Vitamin B12 and Cardiovascular Disease (CVD) 
 
Nutritional risk factors for CVD include hypercholesterolaemia, hypertension and obesity. Elevated 
tHcy concentrations are also considered a risk factor, however, it is unclear if tHcy is a modifiable risk 
factor or an independent marker of the disease process. Much of the research into CVD and tHcy is 
related to the effects of folate supplementation with or without the addition of vitamins B12 and B6. 
Investigations of the relationship between CVD and vitamin B12 per se are limited. 
Meta-analyses of prospective studies (Table 3) have consistently shown associations between tHcy 
and increased risk of CVD. Supplementation with vitamin B12 of doses ranging from 0.02–1 mg/d 
produces approximately 7% reduction in tHcy, while folate produces 10–30% reduction in risk. 
Vitamin B6 has been shown to have little effect [52]. 
Table 3. Meta-analyses of studies assessing vitamin B12 and CVD. 
Trial 
Type 
 
Study Details 
Main Outcome 
 
Meta-
analysis 
[53]  
9 case-control studies. Assessed associations 
between tHcy and CVD risk. 
5µM tHcy increment associated with increased risk of 
CAD, OR = 1.6 (95% CI:1.4 to 1.7) for males and 1.8 
(95% CI:1.3 to 1.9) for females. 
Meta-
analysis 
[54]  
30 prospective or retrospective studies assessed 
tHcy and CVD risk. 
25% lower tHcy associated with lower risk of IHD & 
stroke. 
Meta-
analysis 
7 RCTs 
[55]  
B vitamin supplementation and tHcy lowering,  
assessed effect of vitamin B12 (range 0.02–1.0 
mg/day) 
Vitamin B12 (median dose 0.4 mg/d) - further decrease 
(-7%) in tHcy Nutrients 2010, 2                                       
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Table 3. Cont. 
Meta-
analysis  
12 RCTs 
[56]  
Preexisting CVD or renal disease- included 3 
studies of vitamin B12 supplementation, with doses 
0.4–1.0 mg B12/day.  
Reduction in stroke risk in vitamin B12 (1 mg/d) 
intervention OR = 0.76 (95% CI:0.59, 0.96) 
Meta-
analysis 
8 RCTs 
[57]  
4 studies assessed vitamin B12 supplementation 
(0.018–1 mg) and stroke risk 
Reduction in stroke greater in longer trials with more 
tHcy lowering and no stroke history. No specific effect 
of vitamin B12. 
Meta-
analysis 
24 RCTs 
[58]  
 
Assessed CIMT: 3 with vitamin B12: 0.4–0.5 mg/d; 
endothelial function: 5 with B12: 6 µg–1 mg/day 
 
↓ CIMT, ↑ FMD found in short-term not long term 
trials 
 
µM = micromolar, tHcy = total homocysteine, CAD = coronary artery disease, OR = odds ratio, 
CI=confidence intervals, CVD = coronary vascular disease, IHD=ischaemic heart disese, CIMT = carotid 
intima media thickness, FMD = flow mediated dilation 
 
The recent B vitamin supplementation trials investigating the effect of tHcy reduction and CVD did 
not show the expected reductions in risk of CVD [59-63]. All of these randomised controlled trials 
(RCTs) included vitamin B12 supplementation (ranging from 6 µg-1 mg) in tandem with folate, and it 
is not possible to determine the individual impact of vitamin B12. A number of reviews have discussed 
the limitations of these trials [64-66] and identified inadequate treatment with vitamin B12 as one of  
the limitations. 
Subgroup analysis of the VISP Trial found that patients with higher baseline vitamin B12 
concentrations, taking high dose vitamins, had the best outcomes and those with lower baseline 
vitamin B12 taking low-dose vitamins had the poorest outcomes for stroke, death, and coronary events, 
suggesting higher vitamin B12 doses may be needed in some patients [67]. Vitamin B12 has been shown 
to be a major determinant of tHcy concentrations in subjects with adequate folate status [68] and the 
existence of vitamin B12 deficiency could be one reason for the lack of effect of intervention with 
folate [69]. 
 
10. Cognitive Decline 
 
The assessment of vitamin B12 status forms part of the screening process for dementia, however, the 
effects of sub-clinical levels of vitamin B12 on cognitive status are unclear. Studies investigating 
cognitive decline and vitamin B12 status using serum vitamin B12 concentrations alone, have been 
inconclusive [70]. Raised MMA concentrations are associated with cognitive decline and Alzheimer’s 
Disease [71]. It has been suggested that holo-TC and MMA and the ratio holo-TC:vitamin B12 [72,73] 
are better correlated with cognition and the rate of cognitive decline in elderly subjects. In older people 
with low vitamin B12 status, a high serum folate concentration was associated with increased odds of 
cognitive impairment, but in subjects with normal vitamin B12 status, high serum folate was found to 
be protective against cognitive impairment [74]. Nutrients 2010, 2                                       
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To date, there are few intervention studies that examine the relationship between vitamin B12 and 
cognitive function. A Cochrane review, based on 2 studies, identified no effect of supplementation 
with vitamin B12 alone on cognitive score in older adults [75]. A meta-analysis and review identified a 
correlation between tHcy and Alzheimer’s Disease, and suggested the effect was due to lower levels of 
vitamins B12, B6 and folate [76]. These studies suggest a role for vitamin B12 in the prevention of 
cognitive decline. However, more long-term studies using biomarkers of vitamin B12 status and 
intervention studies from mid-life are needed to determine the effects of B vitamins on cognition. 
 
11. Osteoporosis 
 
Dietary factors associated with the development of osteoporosis include inadequate protein, calcium 
and vitamin D. More recently, there has been interest in the effect of other nutrients, including vitamin 
B12 on bone health. 
Elevated tHcy has been associated with an increased risk of bone fractures, however it is not clear 
whether this is related to tHcy per se, to the level of vitamins B12, B6 or folate which are required for 
its metabolism, or to other causes of elevated tHcy such as environmental factors or underlying 
disease. A recent systematic review found that there is evidence for the association between tHcy and 
increased fracture risk, but less conclusive evidence for tHcy and low bone mineral density (BMD) or 
for the association between vitamin B12 and either fracture risk or low BMD [77]. Intervention trials of 
the association between B vitamin supplementation have also shown mixed results. 
Positive effects of the supplementation of B vitamins on BMD have been found in a subgroup of 
osteoporotic patients with high tHcy and stroke patients at risk for osteoporosis [78,79], but none in a 
group of healthy older people or from the secondary analysis of the HOPE Trial for CVD   
reduction [80,81]. Cohort studies with more than 1,000 subjects or smaller intervention trials are 
summarized in Table 4. Some of the inconsistencies in study results may be due to differences in the 
study populations [82,83], differences in the cut points used to define vitamin B12 status, and the 
reliance on serum vitamin B12 concentrations rather than more specific biomarkers. 
Table 4. Studies of vitamin B12 and risk of osteoporosis or fracture. 
Design 
and 
reference 
Study Details  Main Outcome  Reduced 
risk 
Cohort 
[84] 
Elderly, fracture risk  Low vitamin B12 and/or HHcy: RR = 3.8 (95% CI:1.2, 1.6) males and 
2.8 (95% CI:1.3, 5.7) females 
Yes 
Cohort 
[85]  
Elderly, fracture risk  tHcy > 14, hip fracture HR = 1.49; (95% CI: 0.91, 2.46)  No 
Cohort 
[86] 
Hip fracture risk  fracture for high vs low tHcy (≥15 vs <9 µM), HR=2.42 (95% 
CI:1.43, 4.09) in women  
Yes 
Cohort 
[87] 
Elderly, fracture risk   For 1 SD in tHcy fracture RR =1.4 (95% CI:1.2, 1.6)   Yes Nutrients 2010, 2                                       
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Table 4. Cont. 
Cohort 
[88] 
Elderly BMD, tHcy, 
MTHFR polymorphisms  
OR for low BMD w HHcy ≥15 µM vs. low tHcy OR=1.96 (95% 
CI:1.40, 2.75) for females.  
Yes 
Cohort 
[89] 
Elderly BMD and plasma 
vitamins 
Vitamin B12 <148 pM had lower BMD at hip (males) and spine 
(females) p < 0.05.  
Yes 
Cohort 
[90] 
Elderly subjects (n=1550)  Serum vitamin B12 <15
th percentile: OR of osteoporosis/osteopenia = 
2.0 (95% CI:1.0, 3.9). 
Yes 
RCT [79]  559 subjects:5 mg folate, 
1.5 mg vitamin B12 or 
placebo 
RR for hip fracture = 0.20 (95% CI: 0.08, 0.50)  Yes 
RCT [78]  47 Osteoporotic subjects 
2.5 mg folate, 0.5 mg 
vitamin B12 and 25 mg B6 
or placebo.  
No changes in BMD or bone metabolism markers.  No 
RCT  
[80] 
Healthy older n = 276; 
folate 1 mg, vitamin B12 
0.5 mg, B6 10 mg or 
placebo.  
No differences in bone markers in vitamin vs placebo groups.  No 
CT  
[81] 
5522 subjects with 
vascular disease, 2.5 mg 
folic acid, 50 mg B6, 1 mg 
vitamin B12 or placebo 
HR =1.06 (95% CI:0.81, 1.40) for fracture risk in supplemented vs 
non supplemented 
No 
HHcy = hyperhomocysteinaemia, tHcy = total homocysteine, CI = confidence intervals, SD = standard 
deviation, RR = relative risk, OR = odds ratio, HR = hazard ratio. 
 
12. Other Aspects of Vitamin B12 and Ageing 
 
Vitamin B12 has been associated with the development of age related macular degeneration (AMD) 
and risk of frailty, both leading causes of disability in the elderly. 
AMD is the leading cause of vision loss in the elderly. Risk factors include increasing age, family 
history, hypertension, smoking, obesity, sunlight exposure and hypercholesterolemia [91].   
Some [91,92] but not all [93] cross sectional studies have found lower vitamin B12 concentrations in 
AMD cases. However, a recent RCT with 5205 female health professionals at risk of vascular disease 
found a 34% reduction in the relative risk of AMD after supplementation with vitamins B12, B6 and 
folate (daily doses of 1 mg, 50 mg, 2.5 mg respectively) [94].  
Frailty is characterized by muscle wasting, diminished strength, often with weight loss with or 
without reduced nutritional intake. Frailty is associated with an increased vulnerability to stresses, 
causing longer and more complicated recovery from illness or surgery [95]. 
Increased risk of frailty and disability has been associated with poor B vitamin status. Subjects with 
vitamins B12 and B6 in the lowest quintiles and subjects with elevated MMA and tHcy concentrations, 
have been found to have increased risk of decline in physical function and the development of   
frailty [96,97]. Two cross sectional studies found the length of hospital stay was associated with poor 
vitamin B12 status as assessed by MMA and serum vitamin B12 concentrations [98,99]. To date there Nutrients 2010, 2                                       
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are limited studies, however, if improvements in nutrition can delay frailty progression, it could 
significantly enhance the independence of the increasing numbers of older people. 
 
13. Conclusion 
 
Vitamin B12 is a particularly important vitamin for women of childbearing age and for older people, 
however, adequate vitamin B12 status over the whole of the lifecycle is needed for optimal health. 
There has been renewed interest in vitamin B12 since the reporting of associations between 
homocysteine and chronic disease, particularly vascular disease. The effects of sub-clinical deficiency 
are not fully known and many aspects of vitamin B12 absorption, bioavailability and metabolism are 
yet to be determined. The identification of sensitive biomarkers of vitamin B12  status will help 
elucidate the relationships between vitamin B12 and chronic disease, and help to identify those at risk 
of clinical and sub-clinical deficiency. 
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